CACDS show includes prescription-ordering kiosk
TORONTO — Industry leaders at an annual retail pharmacy conference in Canada got a look at a kiosk that allows patients to order prescription drugs through an Internet connection.
TCE Group announced the introduction of its Pharma Kiosk, or PK+ terminal at the annual meeting of the Canadian Association of Chain Drug Stores in Toronto.
"Many of the high-level leaders we spoke to during the conference embraced this type of industry change by using technology to increase customers’ confidence," TCE Group president Amr Bannis said. "Many influential leaders understand that customers are so busy with work and other family obligations, it is often difficult to find the time to stand in line at traditional pharmacies and wait while their prescriptions are being filled."
The kiosk is designed to be located at any site, including such remote locations as office towers and shopping malls.
"By offering a PK+ terminal on site where customers work or shop, drug stores can offer yet another way to help them save time and money by filling their prescriptions via PK+ and receiving related healthcare services and information," Bannis said.
Q&A: Manning up
Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements.
DSN: Men aren’t too proactive addressing their own health issues. How do you market to them?
Marty Gallant: Here’s the bottom line: A man will never admit he’s having problems. … Our market research has shown that when it comes to the retail-end, it’s the wife who usually does the purchasing.
DSN: Men are known to lose muscle mass after age 40; does testosterone help improve muscle function?
Gallant: That’s exactly what it is. If you can keep your testosterone levels high, then you’re not going to lose the muscle mass.
DSN: John Sally, NBA-all star, serves as a spokesman for these products. How did that come about?
Gallant: I met John at a natural products show. … We spent about an hour talking, and he told me about how his father and his brother had prostate issues, and that he travels the country discussing prostate health for the Prostate Cancer Foundation.
To listen to the full audio Q&A, click here.
NewsBytes — Chain Pharmacy, 11/5/12
FDA approves cardiovascular drug
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain. Actavis announced the approval of diltiazem hydrochloride extended-release capsules. The drug is a generic version of Valeant’s Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.
GPhA appoints CVS Caremark public policy director to head policy shop
WASHINGTON — An executive from CVS Caremark will guide policy for a generic drug industry trade association. The Generic Pharmaceutical Association said that it had appointed CVS Caremark senior director of public policy Christine Simmon to run its policy shop as SVP policy and strategic alliances, effective Oct. 24. Christine Simmon previously worked for the GPhA as VP policy, public affairs and development from 2002 to 2006.
“We are delighted to welcome Christine back to our professional team,” GPhA president and CEO Ralph Neas said. “Her vast experience working with legislators, regulatory agencies and industry leaders on key healthcare issues will serve our industry well. She will play a leading role in our mission to show that safe, effective and affordable generic medicines are a critical part of the solution to controlling costs and lowering the nation’s healthcare bill.”
Simmon also will help expand the GPhA’s partnerships with other industry, consumer and public policy organizations, the group said.
Ranbaxy launches authorized
generic for dry mouth
PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said.
The India-based generic drug maker announced the launch of cevimeline hydrochloride in the 30-mg strength under an agreement with parent company Daiichi Sankyo. The drug is used in patients with Sjogren’s syndrome, which affects the moisture- producing glands.
Daiichi Sankyo markets the drug under the name Evoxac. The drug had sales of $62.4 million during the 12-month period ended in June 2011, according to IMS Health.
An authorized generic is a branded drug marketed under its generic name at a lowered price. Apotex is marketing the generic version of the drug.
Mylan settles respiratory drug suit
PITTSBURGH — Mylan has settled a patent infringement suit over a drug used to treat respiratory diseases, Mylan said. The generic drug maker said it resolved a patent litigation suit filed by Shionogi and Cima Labs over prednisolone sodium phosphate orally disintegrating tablets, a generic version of Orapred ODT. Mylan is hoping to market its generic version of the drug in the 10-mg, 15-mg and 30-mg strengths. The drug is used to treat asthma and certain allergic conditions.
Under the settlement, Mylan will be able to launch its product starting in April 2014. The company said it was likely the first company to file a regulatory approval application containing a Paragraph IV certification, a legal assertion that the patent covering the branded drug is invalid, unenforceable or not at risk of being infringed.
Orapred ODT had sales of $33.1 million during the 12-month period ended in June, according to IMS Health.